These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 17035872

  • 1. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
    Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Ni ZH, Nelson R.
    Invest Radiol; 2006 Nov; 41(11):815-21. PubMed ID: 17035872
    [Abstract] [Full Text] [Related]

  • 2. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L, Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study.
    Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.
    Sahani DV, Soulez G, Chen KM, Lepanto L, Xu JR, Nelson RC, Grazioli L, Vanzulli A, Heiken JP, Investigators of the IMPACT Study.
    Invest Radiol; 2007 Dec; 42(12):856-61. PubMed ID: 18007158
    [Abstract] [Full Text] [Related]

  • 5. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.
    Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ.
    AJR Am J Roentgenol; 2008 Jul; 191(1):151-7. PubMed ID: 18562739
    [Abstract] [Full Text] [Related]

  • 6. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH, Choi DJ, Youn TJ, Yoon CH, Suh JW, Kim KI, Cho YS, Cho GY, Chae IH, Kim CH.
    Am J Cardiol; 2011 Jul 15; 108(2):189-94. PubMed ID: 21545991
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of patient comfort between iodixanol and iopamidol in contrast-enhanced computed tomography of the abdomen and pelvis: a randomized trial.
    Weiland FL, Marti-Bonmati L, Lim L, Becker HC.
    Acta Radiol; 2014 Jul 15; 55(6):715-24. PubMed ID: 24060817
    [Abstract] [Full Text] [Related]

  • 9. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures.
    Laskey W, Aspelin P, Davidson C, Rudnick M, Aubry P, Kumar S, Gietzen F, Wiemer M, DXV405 Study Group.
    Am Heart J; 2009 Nov 15; 158(5):822-828.e3. PubMed ID: 19853704
    [Abstract] [Full Text] [Related]

  • 10. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
    Thomsen HS, Morcos SK.
    Eur Radiol; 2009 Apr 15; 19(4):891-7. PubMed ID: 19002467
    [Abstract] [Full Text] [Related]

  • 11. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.
    Hardiek KJ, Katholi RE, Robbs RS, Katholi CE.
    J Diabetes Complications; 2008 Apr 15; 22(3):171-7. PubMed ID: 18413220
    [Abstract] [Full Text] [Related]

  • 12. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):924-30. PubMed ID: 16949481
    [Abstract] [Full Text] [Related]

  • 13. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.
    Cheruvu B, Henning K, Mulligan J, Klippenstein D, Lawrence D, Gurtoo L, Gottlieb RH.
    J Comput Assist Tomogr; 2007 Sep 05; 31(4):493-8. PubMed ID: 17882021
    [Abstract] [Full Text] [Related]

  • 14. N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study.
    Staniloae CS, Doucet S, Sharma SK, Katholi RE, Mody KR, Coppola JT, Solomon R.
    J Interv Cardiol; 2009 Jun 05; 22(3):261-5. PubMed ID: 19490358
    [Abstract] [Full Text] [Related]

  • 15. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP, Winter JP, Nguyen-Do P, Lo S, French JK, Hallani H, Fernandes C, Jepson N, Leung DY.
    Intern Med J; 2009 Jan 05; 39(1):25-31. PubMed ID: 18771430
    [Abstract] [Full Text] [Related]

  • 16. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, Costello P, Schoepf UJ.
    Radiology; 2008 Jul 05; 248(1):97-105. PubMed ID: 18483232
    [Abstract] [Full Text] [Related]

  • 17. Comparative investigation of i.v. iohexol and iopamidol: effect on renal function in low-risk outpatients undergoing CT.
    Dillman JR, al-Hawary M, Ellis JH, Cohan RH, Kaza R, Myles JD, Khalatbari S, Francis IR.
    AJR Am J Roentgenol; 2012 Feb 05; 198(2):392-7. PubMed ID: 22268183
    [Abstract] [Full Text] [Related]

  • 18. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):958-65. PubMed ID: 19021282
    [Abstract] [Full Text] [Related]

  • 19. Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial.
    Rosenberg C, Martínez-Rodrigo JJ, Lonjedo Vicent E, Macho J, Lim L, Todoran TM, Peripheral Discomfort Study Investigator Panel.
    J Invasive Cardiol; 2017 Jan 01; 29(1):9-15. PubMed ID: 28045670
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
    Sandstede JJ, Roth A, Machann W, Kaupert C, Hahn D.
    Eur J Radiol; 2007 Jul 01; 63(1):120-3. PubMed ID: 17317065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.